Chinares pharma (03320.HK) announced that its subsidiary, china resources double-crane pharmaceutical, has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for semaglutide injection.

As a major multi-indication product in the field of endocrinology, semaglutide has been approved for clinical trials for the indication of long-term weight management as an adjunct to diet and exercise.